DOCSLIB.ORG

Quarterly Performance Review Uk Smaller Companies Fund W - Acc Shares 30 June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quarterly Performance Review Uk Smaller Companies Fund W - Acc Shares 30 June 2021 QPR.en.xx.20210630.GB00B7VNMB18.pdf For Investment Professionals Only FIDELITY INVESTMENT FUNDS QUARTERLY PERFORMANCE REVIEW UK SMALLER COMPANIES FUND W - ACC SHARES 30 JUNE 2021 Portfolio manager: Jonathan Winton Performance over quarter in GBP (%) Performance for 12 month periods in GBP (%) Fund 11.4 Market index 5.5 Numis UK Smaller Companies ex Inv Cos Index (Gross) Market index is for comparative purposes only. Source of fund performance is Fidelity. Basis: bid-bid with income reinvested, in GBP, net of fees. Other share classes may be available. Please refer to the prospectus for more details. Fund Index Market Environment UK equities rose over the second quarter. Markets started on a strong note on increasing optimism around the prospects of a reopening given an acceleration in vaccination rollouts. A sharp pick-up in corporate earnings and continued strength in economic data boosted investor sentiment. However, a pick-up in inflation readings led to some concerns. While the Bank of England (BoE) continues to see the current inflation pressures as transitory, the US Federal Reserve’s (Fed) more aggressive tone temporarily unsettled markets. Meanwhile, worries about the spread of a more transmissible COVID-19 variant led to a more cautious stance. For the most part, vaccines appear to be keeping hospitalisation rates under control, but virus concerns remain a source of worry going forward. In this environment, most sectors reported flat to positive returns, with the decline in bond yields helping growth stocks and bond proxies outperform. Health care and utilities were among the biggest gainers, while more cyclical sectors such as financials and consumer discretionary underperformed. The UK economy appears to be on course for a strong rebound, supported by the easing of social distancing restrictions, as evidenced by the latest economic indicators. For instance, the latest GDP estimates suggest an expansion of 2.3% in April, the fastest monthly rise since July 2020, with strong retail spending and the resumption of schooling supporting growth. Similarly, business activity picked up momentum and saw record growth during the quarter, according to IHS Markit. As the economy recovered from the pandemic, inflation rose sharply over the quarter to 2.1% in May, marginally breaching the BoE’s 2% target. Fund Performance In the second quarter, the W-ACC share class of the fund returned 11.4% in GBP terms; while the Numis UK Smaller Companies ex Investment Companies Index (Gross) returned 5.5%. At a sector level, strong stock selection in the consumer discretionary, industrials, financials and technology sectors supported returns. Merger & acquisition (M&A) activity drove gains M&A activity was a contributing factor to the fund’s outperformance with John Laing, an infrastructure investor bid for by KKR at a significant premium, in a deal valued at about £2 billion, and another holding Spire Healthcare bid for by Australian hospital operator Ramsay Health Care. Notable contributors LSL Property Services was another notable contributor, as it announced robust first quarter earnings at the end of April on the back of strong trading momentum. Sanderson Design was another leading contributor. The company reported encouraging results for the year, underpinned by a strong performance in the second half of the year which saw trading recovering to pre-pandemic levels. Whilst Sanderson is seeing a considerable amount of positive internal change, the backdrop of a strong housing market is also helping the business. Key detractors There was limited downside from portfolio holdings during the quarter. The position in agricultural services group Origin Enterprises fell owing to a weak outlook. Unfavourable weather has resulted in the business losing money in the first half, but rebased consensus expectations, favourable Spring weather and the potential for recovery in the UK next year are expected to improve its prospects. Just Group was another notable detractor. Fund Positioning The near-term UK economic outlook remains supportive with real time data suggesting a continued rebound in activity, back to pre-COVID levels in some instances and even ahead in certain areas. While the recent pick-up in the number of infections caused by the new now dominant Delta variant is a concern, it looks like two vaccine doses provide significant protection. Encouragingly, the vaccine rollout continues to progress at pace. We have not changed the fund’s positioning significantly in recent months, and continue to own names, which we feel are attractively valued with a positive outlook. Attractively valued portfolio Despite the strong market returns seen over the past year, we continue to see good upside, with our holdings trading on average PE of less than 12x 22e. While a lot of global markets look expensive versus their 10-year historical range, the UK market continues to look attractive relative to its own history and global peers, trading at a significant discount to other major developed markets. This is enabling us to find attractively valued companies of better quality than would normally be the case. Key transactions during the quarter During the quarter, we bought a new position in Midwich which should benefit from a fragmented AV market, as the company offers the biggest product range and is difficult to compete with. The exposure to Ten Entertainment, a leading UK operator of entertainment centres, was also increased as there are only two businesses that dominate the industry, which is seeing pent-up demand, and therefore are likely to take market share from smaller players. Important Information Past performance is not a reliable indicator of future results. The fund's returns can be affected by fluctuations in currency exchange rates. The value of investments and any income from them may go down as well as up and an investor may not get back the amount invested. The use of financial derivative instruments may result in increased gains or losses within the fund. This fund invests more heavily than others in smaller companies, which can carry a higher risk because their share prices may be more volatile than those of larger companies. Liquidity is a measure of how easily an investment can be converted into cash. Under certain market conditions assets may be difficult to sell. QPR.en.xx.20210630.GB00B7VNMB18.pdf For Investment Professionals Only FIDELITY INVESTMENT FUNDS QUARTERLY PERFORMANCE REVIEW UK SMALLER COMPANIES FUND W - ACC SHARES 30 JUNE 2021 Attribution Performance attribution is produced in the currency shown below. For funds with multiple share classes, the attribution return reflects the aggregate performance across all the share classes. It may therefore deviate from the published return for a particular share class. When using the analysis for hedged share classes, please consider that the attribution is shown before the impact of hedging. The contributions shown in the tables are before the impact of charges. If charges are applied, their effect is captured in the “Other” category in the tables and will also be reflected in the fund return. All investments, including derivatives, linked to a particular issuing company have been combined to form a total percentage for each issuing company. The sector/industry and geographic contribution tables (where relevant) display a maximum of eleven individual entries. Where applicable, only top five and bottom five are listed, with the remaining contribution shown in the "Other Sectors" or “Others” category. Currency of attribution UK Sterling (GBP) Three month relative return (%) 5.90 Position Contribution (%) 3 months Average Relative Average Relative Relative Performance Relative Performance TOP CONTRIBUTORS Weight Contribution TOP DETRACTORS Weight Contribution LSL PROPERTY SERVICES PLC 1.6 0.55 INVESTEC PLC -1.2 -0.28 JOHN LAING GROUP PLC 2.2 0.53 WATCHES OF SWITZERLAND GROUP LTD -1.2 -0.23 KIN AND CARTA PLC OLD 1.1 0.46 JUST GROUP PLC 1.1 -0.20 SANDERSON DESIGN GROUP PLC 2.1 0.42 ST MODWEN PROPERTIES PLC -0.7 -0.20 ELECTRA PRIVATE 0.7 0.35 ORIGIN ENTERPRISES PLC 1.0 -0.19 SPIRE HEALTHCARE GROUP PLC 0.9 0.34 OXFORD BIOMEDICA PLC -0.6 -0.16 MIDWICH GROUP PLC 0.9 0.33 LIONTRUST ASSET MANAGEMENT PLC -0.6 -0.16 ARGO BLOCKCHAIN PLC -0.3 0.27 SANNE GROUP PLC -0.7 -0.15 TYMAN PLC 1.3 0.27 DISCOVERIE GROUP PLC -0.5 -0.15 TP ICAP GROUP PLC -0.9 0.26 H&T GROUP PLC 1.0 -0.15 Positions in other funds - including ETFs (Exchange Traded Funds) - can appear in this table, but index derivatives form part of an "Index / Unclassified" category which will appear in the table(s) below when relevant. Names of any positions being shorted at the reporting date have been withheld in line with Fidelity’s disclosure policy. Sector/Industry Contribution (%) 3 months CONTRIBUTIONS TO RELATIVE RETURN Average Sector/ Total Relative Security Industry Relative GICS Sector Weight Selection Selection Contribution Industrials 2.5 1.08 0.55 1.63 Consumer Discretionary 5.2 -0.03 1.04 1.00 Information Technology -3.9 0.25 0.63 0.88 Communication Services 2.7 0.16 0.61 0.77 Financials -2.5 0.31 0.21 0.51 Materials -0.3 0.35 0.04 0.40 Real Estate -4.8 0.32 -0.05 0.27 Energy -0.7 0.27 -0.02 0.25 Health Care -1.0 0.14 0.09 0.23 Consumer Staples -0.8 0.01 0.17 0.17 Utilities -0.6 -0.02 0.10 0.08 Index / Unclassified 4.7 -0.05 0.00 -0.05 Total Primary Assets 0.5 2.80 3.36 6.16 Other* -0.5 -0.26 TOTAL 0.0 5.90 *Other includes portfolio components not already listed such as cash, expenses and other miscellaneous items.
Load more

Recommended publications
  • Morning Wrap
    Morning Wrap Today ’s Newsflow Equity Research 19 Jul 2019 08:16 BST Upcoming Events Select headline to navigate to article Paper and Packaging Stora Enso reports weak Q2, Company Events flagging lower box prices 19-Jul Close Brothers Group; Q419 Trading Update Stora Enso ; Q219 Results Building Materials US non-residential forecasts are 23-Jul Paragon Banking; Q319 Trading Update revised down 24-Jul Britvic; Q319 Trading Update Kindred Group; Q219 Results UK Banks CBG issues a disappointing pre-close trading Marston's; Q319 Trading Update Metro Bank; Q219 Results update – NIM in focus 25-Jul AIB Group; Q219 Results Bankinter; Q219 Results Breedon Group; Interim results Howden Joinery; H1 results International Paper; Q219 Results Permanent TSB; Q219 Results Tyman; H1 results Unilever PLC; Q219 Results Wizz Air; Q120 Results Economic Events Ireland 22-Jul PPI June19 Wholesale Price Index June19 26-Jul Retail Sales June19 United Kingdom 23-Jul CBI Industrial Trends July19 25-Jul CBI Distributive Trades July19 United States Europe This document is intended for the sole use of Goodbody Stockbrokers and its affiliates Goodbody Capital Markets Equity Research +353 1 6419221 Equity Sales +353 1 6670222 Bloomberg GDSE<GO> Goodbody Stockbrokers UC, trading as “Goodbody”, is regulated by the Central Bank of Ireland. In the UK, Goodbody is authorised and subject to limited regulation by the Financial Conduct Authority. Goodbody is a member of the Irish Stock Exchange and the London Stock Exchange. Goodbody is a member of the FEXCO group of companies. For the attention of US clients of Goodbody Securities Inc, this third-party research report has been produced by our affiliate, Goodbody Stockbrokers Goodbody Morning Wrap Paper and Packaging Stora Enso reports weak Q2, flagging lower box prices Stora Enso has reported Q2 results to the end of June.
    [Show full text]
  • Annual Report and Accounts for the Year Ended 31 December 2020
    Tyman plc Annual report and accounts TYMAN PLC for the year ended 31 December 2020 Annual report and accounts for the year ended 31 December 2020 Annual report and accounts for the year The expert touch that transforms Tyman is a leading international supplier of engineered fenestration components and access solutions to the construction industry. Highlights • Strong recovery from COVID-19 in H2 saw growth of 5% against £572.8m 1.1× 4.0p £100.6m H2 2019; full year LFL revenue down 6% Revenue Leverage* Dividend per share Adjusted net debt* • Cost reductions and benefits of self-help initiatives mitigated the full (2019: £613.7m) (2019: 1.7×) (2019: 3.9p) (2019: £164.5m) year revenue shortfall, resulting in adjusted operating margin slightly ahead of 2019 and LFL adjusted operating profit down only 6% • Good progress on self-help measures: £80.3m 27.2p £47.6m 19.1p − Encouraging level of North American customer wins Adjusted operating profit* Adjusted earnings per share* Profit before taxation Basic earnings per share − Successful execution of planned footprint realignments (2019: £85.4m) (2019: 27.5p) (2019: £24.8m) (2019: 9.1p) − Momentum gained with continuous improvement activities • Strategic initiatives continued to bear fruit, driving market share gains across the Group • Reduction in safety incidents of 22% indicative of operational excellence progress • Strong cash generation with cash conversion of 131% and reduction in leverage to 1.1x, achieving low-end of new target range • Repayment in December 2020 of £2.3m received under
    [Show full text]
  • ES River and Mercantile UK Recovery Fund
    ES River and Mercantile UK Recovery Fund Quarterly Report to 30 September 2020 UK Equity Unconstrained Fund I Monthly Report Month 2008 UK Recovery For unitholders only0 ES R&M UK Recovery Fund Quarter 3, 2020 Fund Objective The investment objective of the Fund is to grow the value of your investment (known as “capital growth”) in excess of the MSCI United Kingdom Investable Market Index (IMI) Net Total Return (the “Benchmark”) over a rolling 5 year period, after the deduction of fees. Performance (net of fees) B share class Benchmark Difference 3 Months -1.4% -3.6% 2.2% 1 Year -17.1% -18.5% 1.4% 3 Years p.a. -5.9% -4.1% -1.8% 5 Years p.a. 3.8% 3.0% 0.8% 10 Years p.a. 7.8% 4.6% 3.1% Since Inception p.a. 12.6% 7.9% 4.7% 20% 10% 0% -10% -20% -30% 3 Months 1 Year 3 Years 5 Years 10 Years Since Inception p.a. p.a. p.a. p.a. ES R&M UK Recovery Fund B Shares MSCI UK IM Index Performance (gross of fees) Z class Z share class Benchmark Difference 3 Months -1.2% -3.6% 2.4% 1 Year -16.2% -18.5% 2.3% 3 Years p.a. -5.0% -4.1% -0.9% 5 Years p.a. 4.8% 3.0% 1.9% 10 Years p.a. 8.9% 4.6% 4.2% Source: River and Mercantile Asset Management LLP. Benchmark is the MSCI UK Investable Market index, net GBP.
    [Show full text]
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • Finn-Ancial Times Finncap Financials & Insurance Quarterly Sector Note
    finn-ancial Times finnCap Financials & Insurance quarterly sector note Q3 2020 | Issue 9 Highlights this quarter: Elevated uncertainty and volatility have been hallmarks of the last 18 months, with Brexit, the UK General Election and more recently COVID-19 all contributing to the challenges that face investors wishing to carve out solid and stable returns amid these ‘unprecedented’ times. With this is mind, and simulating finnCap’s proven Slide Rule methodology, we found the highest quality and lowest value stocks across the financials space, assessing how the make-up of these lists changed over the period January 2019 to July 2020, tracking indexed share price performance over the period as well as movements in P/E and EV/EBIT valuations. The top quartile list of Quality companies outperformed both the Value list and the FTSE All Share by rising +2.5% over the period versus -5.4% for the All Share and -14.3% for Value stocks. Furthermore, the Quality list had protection on the downside in the market crash between February and March 2020, and accelerated faster amid the market rally between late March and July 2020. From high to low (January to March), Quality moved -36.3% against the Value list at -45.5%, while a move off the lows to July was +37.4% for Quality and +34.0% for Value. There was some crossover between the Quality and Value lists, with 7 companies of the top quartile (16 companies in total) appearing in both the Quality and Value lists. This meant that a) investors could capture what we call ‘Quality at Value’ (i.e.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • FTSE Factsheet
    FTSE COMPANY REPORT Share price analysis relative to sector and index performance Duke Royalty DUKE Investment Banking and Brokerage Services — GBP 0.4125 at close 10 August 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 10-Aug-2021 10-Aug-2021 10-Aug-2021 0.45 140 140 1D WTD MTD YTD Absolute -2.4 -1.2 -1.8 35.2 130 130 0.4 Rel.Sector -2.4 -0.5 -3.6 25.9 Rel.Market -2.8 -1.7 -3.7 20.9 120 120 0.35 VALUATION 110 110 0.3 Trailing 100 100 Relative Price Relative Price Relative 0.25 PE -ve Absolute Price (local (local currency) AbsolutePrice 90 90 EV/EBITDA -ve 0.2 80 80 PB 2.0 PCF 28.1 0.15 70 70 Div Yield 4.6 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Price/Sales -ve Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.2 90 90 90 Div Payout -ve 80 80 80 ROE -ve 70 70 70 Share Index) Share Share Sector) Share - 60 - 60 60 DESCRIPTION 50 50 50 40 40 The Company is a globally focused investment 40 RSI RSI (Absolute) 30 30 company specialising in diversified royalty investment.
    [Show full text]
  • Stoxx® Europe Ipo (60 Months) Index
    STOXX® EUROPE IPO (60 MONTHS) INDEX Components1 Company Supersector Country Weight (%) CELLNEX TELECOM Telecommunications ES 6.13 DELIVERY HERO Retail DE 5.29 JUST EAT TAKEAWAY.COM NV Retail NL 5.21 SCOUT24 Technology DE 3.41 COVESTRO Chemicals DE 2.72 AUTO TRADER GROUP Media GB 2.50 HELLOFRESH AG Retail DE 2.18 AMUNDI Financial Services FR 2.08 KOJAMO OYJ Real Estate FI 2.00 GALENICA SANTE AG Retail CH 1.92 VAT GROUP AG Industrial Goods & Services CH 1.91 ASR NEDERLAND NV Insurance NL 1.79 SIG COMBIBLOC GROUP AG Industrial Goods & Services CH 1.72 CONVATEC PLC Health Care GB 1.70 SIGNIFY Industrial Goods & Services NL 1.54 NEXI SPA Industrial Goods & Services IT 1.50 TEAMVIEWER AG Technology DE 1.49 INWIT Telecommunications IT 1.43 AVAST PLC Technology GB 1.41 LA FRANCAISE DES JEUX Travel & Leisure FR 1.28 STADLER RAIL AG Industrial Goods & Services CH 1.19 BAWAG GROUP AG Banks AT 1.05 NETCOMPANY GROUP AS Technology DK 1.03 SOFTCAT Technology GB 0.89 PIRELLI & C. S.P.A. Automobiles & Parts IT 0.89 COUNTRYSIDE PROPERTIES PLC Personal & Household Goods GB 0.88 LANDIS GYR GROUP AG Industrial Goods & Services CH 0.86 INTEGRAFIN HOLDINGS PLC Financial Services GB 0.81 DOMETIC GROUP AB Personal & Household Goods SE 0.77 BRAVIDA HOLDING AB Industrial Goods & Services SE 0.72 SILTRONIC Technology DE 0.69 TRAINLINE PLC Travel & Leisure GB 0.68 SPIE Industrial Goods & Services FR 0.68 INTERTRUST NV Financial Services NL 0.68 ZUR ROSE GROUP Retail CH 0.66 ASCENTIAL PLC Media GB 0.64 SINCH Technology SE 0.64 Virgin Money UK Banks GB 0.62 HASTINGS
    [Show full text]
  • Sanne Group Plc Annual Report and Accounts 2020 1 Sanne at a Glance
    Annual Report and Accounts 2020 Sanne is a leading global provider of alternative asset and corporate services. Contents 01 03 04 Introduction Governance Financial Statements 01 Financial and operational highlights of 56 Chairman’s Introduction 110 Independent Auditors' Report YMJ࣢^JFW 58 Corporate Governance Report 118 Consolidated Income Statement 02 Sanne at a glance 60 Board of Directors 119 Consolidated Statement of Comprehensive Income 62 Sanne’s Executive Committee 120 Consolidated Balance Sheet 02 63 Leadership 121 Consolidated Statement of Changes in Equity 64 Board Effectiveness Strategic Report 122 Consolidated Cash Flow Statement 70 Directors’ Report 123 Notes to the Consolidated 06 Chairman’s Statement 74 Nomination and Governance Financial Statements Committee Report 08 Chief Executive Officer’s Statement 171 Glossary of Terms 77 Audit Committee Report 12 Value Chain 173 Shareholder and Corporate Information 82 Risk Committee Report 14 Business Model 85 Directors’ Remuneration at-a-glance 16 Our Stakeholders 86 Remuneration Committee Report 20 Strategy Review 97 Annual Report on Remuneration 24 Key Performance Indicators 107 Directors’ Responsibilities Statement 28 Segmental Review 30 Chief Financial Officer’s Review 34 Alternative Performance Measure definitions 36 ESG and Sustainability 46 Risk Management 52 Viability Statement www.sannegroup.com/annualreport Introduction Strategic Report Governance Financial Statements Financial and operational highlights of the year Robust financial performance, 2 1 with strong profit
    [Show full text]
  • Tyman Plc Annual Report and Accounts 2016 Accounts and Report Annual
    Tyman plc Tyman Annual Report and Accounts 2016 A year of growth Tyman plc Annual Report and Accounts 2016 Further progress and growth through acquisitions Tyman is a leading international supplier of engineered components to the door and window industry. At 31 December 2016 the Group had 23 manufacturing sites in eight countries along with a further 18 sourcing and distribution sites across North America, Europe, South America, Asia and Australasia with its products being found in homes and buildings worldwide. Operational highlights Financial highlights • Year of profitable growth assisted by contributions from strategic acquisitions and favourable exchange rates Revenue Dividend per share • Integration of the three acquisitions completed in the year now well advanced £457.6m 10.50p 2015: £353.4m +29% 2015: 8.75p +20% • Synergy targets for both Giesse and Bilco now expected to be achieved by the end of 2017 - significantly ahead of schedule Underlying operating profit Underlying net debt • Strong cash generation and tight control over working £69.8m £176.7m capital taking Leverage back below 2.00x at the year end 2015: £51.4m +36% 2015: £83.2m (112)% • Dividend increased by 20.0 per cent to reflect improved cash generation and profitability Profit before taxation Leverage • Continued margin progression in AmesburyTruth despite limited volume growth £29.4m 1.89x 2015: £15.6m +89% 2015: 1.35x • Stronger second half for ERA with UK markets holding up better than expected post the EU Referendum Underlying earnings per share Return on capital
    [Show full text]